Clinical Trials Browser

Triple Negative Breast Neoplasms × Dasatinib × Clear all

NCT06355037 2024-07-08

Dasatinib Combined With Quercetin to Reverse Chemo Resistance in Triple Negative Breast Cancer

Phase 2 Recruiting

Triple Negative Breast Neoplasms

NCT02720185 2022-06-03

Window of Opportunity Trial of Dasatinib in Operable Triple Negative Breast Cancers With nEGFR

Phase 2 Terminated

5 enrolled 12 charts

Breast Neoplasms, Triple Negative Breast Neoplasms